S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle

Apellis Pharmaceuticals (APLS) Stock Forecast, Price & News

$38.04
-1.63 (-4.11%)
(As of 09/29/2023 ET)
Compare
Today's Range
$37.93
$40.42
50-Day Range
$23.65
$48.53
52-Week Range
$19.83
$94.75
Volume
1.86 million shs
Average Volume
2.66 million shs
Market Capitalization
$4.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.13

Apellis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
73.9% Upside
$66.13 Price Target
Short Interest
Bearish
11.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.61mentions of Apellis Pharmaceuticals in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$10.57 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.89) to ($2.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

132nd out of 972 stocks

Pharmaceutical Preparations Industry

42nd out of 451 stocks


APLS stock logo

About Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

APLS Price History

APLS Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4%
Robert W. Baird Remains a Buy on Apellis Pharmaceuticals (APLS)
See More Headlines
Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Company Calendar

Last Earnings
7/31/2023
Today
10/01/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLS
Fax
N/A
Employees
767
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$66.13
High Stock Price Forecast
$141.00
Low Stock Price Forecast
$29.00
Forecasted Upside/Downside
+73.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
15 Analysts

Profitability

Net Income
$-652,170,000.00
Net Margins
-356.02%
Pretax Margin
-356.37%

Debt

Sales & Book Value

Annual Sales
$75.42 million
Book Value
$1.54 per share

Miscellaneous

Free Float
108,907,000
Market Cap
$4.48 billion
Optionable
Not Optionable
Beta
1.08

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Cedric Francois M.D. (Age 51)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $1.2M
  • Dr. Pascal Deschatelets Ph.D. (Age 53)
    Co-Founder & Chief Scientific Officer
    Comp: $688.05k
  • Mr. Alec  Machiels J.D.Mr. Alec Machiels J.D. (Age 50)
    MBA, Co-Founder & Director
    Comp: $72.5k
  • Mr. Timothy E. SullivanMr. Timothy E. Sullivan (Age 52)
    CFO & Treasurer
    Comp: $716.41k
  • Mr. David O. Watson Esq.Mr. David O. Watson Esq. (Age 50)
    J.D., Gen. Counsel
    Comp: $675.35k
  • Mr. Adam J. TownsendMr. Adam J. Townsend (Age 46)
    Chief Commercial Officer
    Comp: $701.61k
  • Ms. Nur  NicholsonMs. Nur Nicholson (Age 54)
    Chief Technical Operations Officer
  • Mr. James G. Chopas CPA (Age 57)
    VP, Corp. Controller & Chief Accounting Officer
  • Ms. Meredith Kaya
    Sr. VP, Investor Relations & Strategic Fin.
  • Ms. Karen  LewisMs. Karen Lewis (Age 51)
    Chief People Officer













APLS Stock - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APLS shares.
View APLS analyst ratings
or view top-rated stocks.

What is Apellis Pharmaceuticals' stock price forecast for 2023?

15 Wall Street analysts have issued twelve-month target prices for Apellis Pharmaceuticals' stock. Their APLS share price forecasts range from $29.00 to $141.00. On average, they anticipate the company's share price to reach $66.13 in the next year. This suggests a possible upside of 73.9% from the stock's current price.
View analysts price targets for APLS
or view top-rated stocks among Wall Street analysts.

How have APLS shares performed in 2023?

Apellis Pharmaceuticals' stock was trading at $51.71 at the start of the year. Since then, APLS shares have decreased by 26.4% and is now trading at $38.04.
View the best growth stocks for 2023 here
.

Are investors shorting Apellis Pharmaceuticals?

Apellis Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 13,610,000 shares, an increase of 10.6% from the August 31st total of 12,310,000 shares. Based on an average daily trading volume, of 4,730,000 shares, the short-interest ratio is presently 2.9 days.
View Apellis Pharmaceuticals' Short Interest
.

When is Apellis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our APLS earnings forecast
.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) posted its earnings results on Monday, July, 31st. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.35) by $0.33. The company earned $95 million during the quarter, compared to analyst estimates of $70.38 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 212.82% and a negative net margin of 356.02%. The company's revenue was up 482.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.46) EPS.

What ETFs hold Apellis Pharmaceuticals' stock?
What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $38.04.

How much money does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $4.48 billion and generates $75.42 million in revenue each year. The company earns $-652,170,000.00 in net income (profit) each year or ($5.83) on an earnings per share basis.

How many employees does Apellis Pharmaceuticals have?

The company employs 767 workers across the globe.

Does Apellis Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.
Read More
How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com.

This page (NASDAQ:APLS) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -